By treating SHR with pressor and sub-pressor doses of AT1 receptor antagonist, Kumai et al. (2008) showed that both attenuated the superoxide levels in BA and MCA, reversed hypertension-induced hypertrophy and oxidative stress, and improved cerebral blood flow autoregulation, suggesting the blockade of Ang II (and its downstream pathways) as the underlying mechanism. Here, AGTR1 is linked to hypertensive disorder.